<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02884726</url>
  </required_header>
  <id_info>
    <org_study_id>CA008-008</org_study_id>
    <nct_id>NCT02884726</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Mesothelin-ADC</brief_title>
  <official_title>A Phase 1 Study of the Safety and Tolerability of BMS 986148 in Subjects With Advanced and/or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of Mesothelin-ADC in
      subjects with advanced and/or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Actual">September 6, 2017</completion_date>
  <primary_completion_date type="Actual">September 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AEs (Adverse Events)</measure>
    <time_frame>Day 1 to 30 days after the last dose of BMS-986148</time_frame>
    <description>AEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of SAEs (Serious Adverse Events)</measure>
    <time_frame>Day 1 to 30 days after the last dose of BMS-986148</time_frame>
    <description>SAEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of AEs</measure>
    <time_frame>Day 1 to 30 days after the last dose of BMS-986148</time_frame>
    <description>AE leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of SAEs</measure>
    <time_frame>Day 1 to 30 days after the last dose of BMS-986148</time_frame>
    <description>SAEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)]</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration (Cavg)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T-half)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration in a dosing interval (Ctau)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of terminal phase (Vz)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Accumulation Index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax Accumulation Index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctau Accumulation Index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau)</measure>
    <time_frame>Day 1 to day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Day 1 to 30 days after the last dose of BMS-986148</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>BMS-986148 intravenous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986148</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-986148 intravenous infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Must have histological confirmation of advanced and/or metastatic solid

        tumors which are expected to express mesothelin

          -  Must have received and either progressed or been intolerant to the standard treatment
             regimen in the advanced or metastatic setting, if such a therapy exists

          -  Must have measurable tumor per Response Evaluation Criteria in Solid Tumors (RECIST)
             or modified RECIST for malignant pleural mesothelioma

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

        Exclusion Criteria:

          -  Cancer metastases in the brain

          -  Uncontrolled or significant cardiovascular disease

          -  Moderate eye disorders

          -  Moderate peripheral neuropathy

          -  Known past or active hepatitis B or C infection

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1040045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

